RhumbLine Advisers
VRDN icon

RhumbLine Advisers’s Viridian Therapeutics VRDN Stock Holding History

RhumbLine Advisers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.6M Buy
126,350
+8,603
+7% +$184K ﹤0.01% 1766
2026
Q2 		$2.16M Buy
117,747
+17,714
+18% +$285K ﹤0.01% 1898
2026
Q1 		$1.96M Buy
100,033
+2,582
+3% +$76.7K ﹤0.01% 1874
2025
Q4 		$3.03M Sell
97,451
-6,909
-7% -$189K ﹤0.01% 1654
2025
Q3 		$2.25M Sell
104,360
-3,025
-3% -$54.6K ﹤0.01% 1843
2025
Q2 		$1.5M Buy
107,385
+2,826
+3% +$38.4K ﹤0.01% 2039
2025
Q1 		$1.41M Buy
104,559
+4,621
+5% +$78.7K ﹤0.01% 1998
2024
Q4 		$1.92M Buy
99,938
+11,594
+13% +$252K ﹤0.01% 1899
2024
Q3 		$2.01M Sell
88,344
-2,482
-3% -$40.6K ﹤0.01% 1910
2024
Q2 		$1.18M Buy
90,826
+23,305
+35% +$323K ﹤0.01% 2152
2024
Q1 		$1.18M Buy
67,521
+7,087
+12% +$137K ﹤0.01% 2163
2023
Q4 		$1.32M Sell
60,434
-63
-0.1% -$995 ﹤0.01% 2124
2023
Q3 		$928K Buy
60,497
+1,015
+2% +$19.4K ﹤0.01% 2252
2023
Q2 		$1.42M Buy
59,482
+6,514
+12% +$167K ﹤0.01% 2105
2023
Q1 		$1.35M Buy
52,968
+5,715
+12% +$183K ﹤0.01% 2005
2022
Q4 		$1.38M Buy
47,253
+12,390
+36% +$285K ﹤0.01% 1979
2022
Q3 		$715K Buy
34,863
+3,150
+10% +$56.6K ﹤0.01% 2328
2022
Q2 		$367K Buy
+31,713
New +$426K ﹤0.01% 2647
2019
Q2 		– Sell
-2,184
Closed -$91K – 3006
2019
Q1 		$91K Sell
2,184
-39
-2% -$1.76K ﹤0.01% 2870
2018
Q4 		$101K Buy
2,223
+754
+51% +$43.6K ﹤0.01% 2882
2018
Q3 		$123K Sell
1,469
-54
-4% -$5.09K ﹤0.01% 2839
2018
Q2 		$146K Buy
1,523
+667
+78% +$70.5K ﹤0.01% 2814
2018
Q1 		$90K Buy
856
+180
+27% +$19.6K ﹤0.01% 2756
2017
Q4 		$106K Sell
676
-153
-18% -$19.5K ﹤0.01% 2766
2017
Q3 		$114K Buy
829
+24
+3% +$4.04K ﹤0.01% 2853
2017
Q2 		$156K Buy
+805
New +$136K ﹤0.01% 2827

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

RhumbLine Advisers's VRDN Position: Q3 2026 in Review

RhumbLine Advisers increased its Viridian Therapeutics (VRDN) stake by 7.3% in Q3 2026, buying an estimated $184K and bringing the position to 126,350 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

RhumbLine Advisers first reported a position in VRDN in Q2 2017 and has held it in 26 quarters since. The position peaked at $3.03M in Q4 2025. 94 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • RhumbLine Advisers held 126,350 shares of Viridian Therapeutics worth $2.6M as of Q3 2026.
  • RhumbLine Advisers bought 8,603 Viridian Therapeutics shares in Q3 2026, an estimated $184K.
  • Viridian Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #1766 holding.
  • RhumbLine Advisers first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 26 quarters since.
  • RhumbLine Advisers's Viridian Therapeutics position peaked at $3.03M in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.